Lucid Diagnostics Stock Today
| LUCD Stock | USD 0.95 0.08 7.77% |
Performance0 of 100
| Odds Of DistressOver 84
|
Lucid Diagnostics is trading at 0.95 as of the 8th of May 2024, a -7.77% down since the beginning of the trading day. The stock's lowest day price was 0.95. Lucid Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Lucid Diagnostics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2024 and ending today, the 8th of May 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 14th of October 2021 | Category Healthcare | Classification Health Care |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.. The company has 49.78 M outstanding shares of which 361.37 K shares are now shorted by private and institutional investors with about 1.23 trading days to cover. More on Lucid Diagnostics
Moving together with Lucid Stock
| 0.84 | DH | Definitive Healthcare | PairCorr |
| 0.8 | AHG | Akso Health Group | PairCorr |
| 0.8 | XAIR | Beyond Air Financial Report 27th of June 2024 | PairCorr |
Moving against Lucid Stock
| 0.76 | GCTK | GlucoTrack | PairCorr |
| 0.72 | DGX | Quest Diagnostics | PairCorr |
| 0.62 | JYNT | Joint Corp | PairCorr |
| 0.58 | SLP | Simulations Plus Financial Report 4th of July 2024 | PairCorr |
| 0.56 | WGS | GeneDx Holdings Corp Financial Report 14th of May 2024 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 20th of May 2024
Lucid Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Lucid Diagnostics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lucid Diagnostics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President COO | Shaun MBA | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Lucid Diagnostics report their recommendations after researching Lucid Diagnostics' financial statements, talking to executives and customers, or listening in on Lucid Diagnostics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Lucid Diagnostics. The Lucid consensus assessment is calculated by taking the average forecast from all of the analysts covering Lucid Diagnostics. | |||||
Lucid Diagnostics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Lucid Diagnostics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lucid Diagnostics' financial leverage. It provides some insight into what part of Lucid Diagnostics' total assets is financed by creditors.
| |||||
Lucid Diagnostics (LUCD) is traded on NASDAQ Exchange in USA. It is located in 360 Madison Avenue, New York, NY, United States, 10017 and employs 70 people. Lucid Diagnostics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lucid Diagnostics's market, we take the total number of its shares issued and multiply it by Lucid Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Lucid Diagnostics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 49.78 M outstanding shares of which 361.37 K shares are now shorted by private and institutional investors with about 1.23 trading days to cover.
Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89.
Check Lucid Diagnostics Probability Of Bankruptcy
Ownership AllocationLucid Diagnostics holds a total of 49.78 Million outstanding shares. Lucid Diagnostics secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 68.21 % of Lucid Diagnostics outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Lucid Ownership Details
Lucid Stock Price Odds Analysis
What are Lucid Diagnostics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Lucid Diagnostics jumping above the current price in 90 days from now is about 70.73%. The Lucid Diagnostics probability density function shows the probability of Lucid Diagnostics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Lucid Diagnostics has a beta of -0.0853. This indicates as returns on the benchmark increase, returns on holding Lucid Diagnostics are expected to decrease at a much lower rate. During a bear market, however, Lucid Diagnostics is likely to outperform the market. Additionally, lucid Diagnostics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Lucid Diagnostics to move above the current price in 90 days from now is about 70.73 (This Lucid Diagnostics probability density function shows the probability of Lucid Stock to fall within a particular range of prices over 90 days) .
Lucid Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Lucid Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lucid Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lucid Diagnostics' value.| Instituion | Recorded On | Shares | |
| Virtu Financial Llc | 2023-12-31 | 20.8 K | |
| Jane Street Group, Llc | 2023-12-31 | 12.3 K | |
| State Street Corporation | 2023-12-31 | 10.5 K | |
| Wells Fargo & Co | 2023-12-31 | 9.1 K | |
| Byrne Asset Management Llc | 2023-12-31 | 6.6 K | |
| Ubs Group Ag | 2023-12-31 | 5.7 K | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 2 K | |
| Tower Research Capital Llc | 2023-12-31 | 1 K | |
| Advisory Services Network, Llc | 2023-12-31 | 765 | |
| Luminus Management, Llc | 2023-12-31 | 773.2 K | |
| Vanguard Group Inc | 2023-12-31 | 332.4 K |
Lucid Diagnostics Historical Income Statement
Lucid Diagnostics Income Statement is one of the three primary financial statements used for reporting Lucid's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Lucid Diagnostics revenue and expense. Lucid Diagnostics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Lucid Diagnostics' Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 2.5 M, whereas Net Loss is projected to grow to (48 M). View More FundamentalsLucid Stock Against Markets
Picking the right benchmark for Lucid Diagnostics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lucid Diagnostics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lucid Diagnostics is critical whether you are bullish or bearish towards Lucid Diagnostics at a given time. Please also check how Lucid Diagnostics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Lucid Diagnostics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Lucid Diagnostics Corporate Management
Elected by the shareholders, the Lucid Diagnostics' board of directors comprises two types of representatives: Lucid Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lucid. The board's role is to monitor Lucid Diagnostics' management team and ensure that shareholders' interests are well served. Lucid Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lucid Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Gordon | General Secretary | Profile | |
| Lishan MD | Chairman CEO | Profile | |
| Joseph MD | Strategic Cofounder | Profile | |
| Michael Parks | Vice Relations | Profile | |
| Adrian Miller | VP Relations | Profile | |
| Amitabh MD | Strategic Cofounder | Profile | |
| Deepika Lakhani | Chief Officer | Profile |
How to buy Lucid Stock?
Before investing in Lucid Diagnostics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Lucid Diagnostics. To buy Lucid Diagnostics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Lucid Diagnostics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Lucid Diagnostics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Lucid Diagnostics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Lucid Diagnostics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Lucid Diagnostics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Lucid Stock please use our How to Invest in Lucid Diagnostics guide.
Already Invested in Lucid Diagnostics?
The danger of trading Lucid Diagnostics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Lucid Diagnostics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Lucid Diagnostics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Lucid Diagnostics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.Note that the Lucid Diagnostics information on this page should be used as a complementary analysis to other Lucid Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Lucid Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 0.058 | Quarterly Revenue Growth 8.286 | Return On Assets (1.01) | Return On Equity (5.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.